Cochlear

Cochlear Limited is an Australian medical-device company headquartered in Sydney and focused on implantable hearing solutions. Its portfolio is built around technologies for people with moderate to profound hearing loss who may not receive sufficient benefit from conventional hearing aids. The company designs, manufactures, supplies, and supports cochlear implants, sound processors, bone-conduction and osseointegrated hearing systems, auditory brainstem implants, wireless accessories, fitting software, and post-implant services. The company traces its commercial origins to Australia’s effort to turn Professor Graeme Clark’s multichannel cochlear-implant research into a clinically usable product. Cochlear was formed in 1981 as a subsidiary of Nucleus, a medical-electronics company, with support that included Australian government finance. The first commercial Nucleus implant was implanted in 1982. The Nucleus 22 later became the first multichannel cochlear implant to receive United States Food and Drug Administration approval, in 1985. These developments established the technological and commercial foundation of the modern Cochlear business. Cochlear became independent from the Nucleus and Pacific Dunlop corporate structure during the 1990s and was publicly listed in 1995. Its business initially centered on cochlear implants, but it subsequently expanded into adjacent hearing-implant categories. In 2004, Cochlear acquired Entific Medical Systems, a Swedish company associated with bone-anchored hearing technology. That transaction helped establish the Baha business as a major part of the company’s portfolio and gave Cochlear a broader position in conductive and mixed hearing loss, single-sided deafness, and related indications. The company operates through a long-term clinical and recipient-support model rather than a conventional consumer-electronics model. A typical customer relationship begins with clinical evaluation, surgery, implantation, activation, and rehabilitation, and can continue for decades through processor upgrades, batteries, coils, accessories, software, repairs, replacement parts, and professional services. This installed-base model makes after-market products and services strategically important. Cochlear also works with surgeons, audiologists, educators, hospitals, researchers, governments, insurers, and recipient organizations. Its principal branded families include Nucleus cochlear-implant systems, Kanso off-the-ear processors, Baha bone-conduction systems, and Osia active osseointegrated implants. Connectivity has become an important part of the brand proposition. Recent processors support smartphone control, wireless streaming, remote-care tools, bimodal hearing configurations, and accessories intended to improve listening in classrooms, workplaces, social settings, and entertainment environments. The company positions these products around lifelong hearing performance, reliability, clinical evidence, device compatibility, and continuity of support. Cochlear’s product development has progressed through successive generations of implants and external processors. Important stages include the Nucleus 24 family, the Freedom implant and processor, the CI500 and Profile implant families, Nucleus 5 and Nucleus 6 processors, the one-piece Kanso processor, the Nucleus 7 and Nucleus 8 processors, Kanso 2 and Kanso 3 processors, and the Osia platform. In 2025, Cochlear introduced the Nucleus Nexa System, combining a new implant with internal memory and upgradeable implant firmware. The company described this architecture as a way to allow future features and improvements to be delivered through both the implanted and external portions of the system. Cochlear has also grown through acquisitions and portfolio changes. In 2022 it announced an agreement to acquire the cochlear-implant business of Demant’s Oticon Medical. Competition concerns led to changes in the scope of the transaction, and the divestment of t…

Cochlear’s history is closely connected with the development of the modern multichannel cochlear implant in Australia. Professor Graeme Clark pursued the technology after observing the effects of hearing loss in his family and working on the engineering and clinical problems involved in stimulating the auditory nerve. His research helped demonstrate that an implant using multiple electrodes could provide useful auditory information rather than merely producing a single sensation of sound. In 1981, Nucleus, an Australian medical-electronics company, established Cochlear as a subsidiary to commercialize the technology. The project received Australian government financial support and brought together medical researchers, engineers, manufacturers, clinicians, and regulators. The first commercial Nucleus cochlear-implant procedure took place in 1982. This early commercial achievement gave the company a foundation in both product development and the specialized clinical infrastructure required for implantation, programming, rehabilitation, and long-term support. The Nucleus 22, also known as the CI22M, became an important regulatory milestone when it received United States FDA approval in 1985 as the first FDA-approved multichannel cochlear implant. Its authorization initially focused on postlingually deaf adults, but later clinical evidence supported expansion to children aged two and older in 1990. The product helped move cochlear implantation from a limited experimental therapy toward an established treatment option for selected patients with severe to profound hearing loss. During the late 1980s, the corporate structure around Cochlear changed. Nucleus was acquired by Pacific Dunlop in 1988, but Cochlear subsequently became a separate publicly listed company when Pacific Dunlop was split up in 1995. The listing gave Cochlear access to public capital and greater independence to pursue international expansion, research, manufacturing, regulatory submissions, and commercial development. Product development proceeded through successive implant and processor families. The Nucleus 24 family, approved in 1998, introduced an implant design with a removable magnet that simplified some MRI considerations. The CI24R and CI24RE families offered different electrode configurations and improvements in power consumption, stimulation, and sound-processing performance. The Freedom implant and processor, introduced during the 2000s, added more advanced processing and offered a rechargeable power option. Cochlear also investigated electric-acoustic stimulation through short-electrode Hybrid implants for recipients who retained useful low-frequency hearing. The Nucleus L24 Hybrid implant received FDA approval in 2014 for adults meeting the relevant candidacy criteria. Cochlear expanded beyond conventional cochlear implants in 2004 through the acquisition of Entific Medical Systems, a Swedish company associated with bone-anchored hearing systems. The transaction added the Baha business and broadened Cochlear’s addressable market to include conductive and mixed hearing loss and certain cases of single-sided deafness. The company also manufactures auditory brainstem implants, which bypass the cochlea and stimulate the cochlear nucleus in the brainstem for patients who cannot use a conventional cochlear implant. External sound processors evolved from early body-worn analog equipment to smaller digital and wireless devices. The ESPrit became Cochlear’s first processor without a separate body-worn unit in 1998. The ESPrit 3G added telecoil functionality in 2002. The Nucleus Freedom followed in 2005, while the Nucleus 5 and Nucleus 6 introduced progressively smaller processors, improved sound processing, multiple battery choices, and compatibility with earlier implants. The Kanso, launched in 2016, was Cochlear’s first one-piece off-the-ear processor. The Nucleus 7, released in 2017, added direct streaming from compatible Apple devices and smartphone-based control. Kanso 2 followed in 2020, and the Nucleus 8 was introduced in 2022. The company’s history also includes product-quality challenges. In 1995, some CI22M implants were recalled because of internal power-supply failures associated with incorrectly installed capacitors; fewer than ten devices reportedly required explantation. In September 2011, Cochlear voluntarily recalled the CI500 implant family after reports of shutdowns or “soft failures.” The recall affected a strategically important product range, led the company to pause production, and caused a substantial fall in its share price. Cochlear returned to the CI24RE platform while investigating the cause and developing replacement products. Cochlear also faced a US compliance case involving its Partners Program. A whistleblower complaint alleged that the program offered credits, discounted products, gifts, travel, and other benefits to physicians and providers in connection with the use of Cochlear devices. In 2010, Cochlear Americas paid US$880,000 to resolve allegations under the Anti-Kickback Statute and False Claims Act. The matter became a prominent example of the regulatory risks associated with commercial activity in implantable medical devices. In 2022, Cochlear agreed to acquire Oticon Medical’s hearing-implant business from Demant. The original proposal covered a wider business, but competition authorities raised concerns about the effect on competition and innovation, particularly in bone-conduction systems. The transaction was narrowed to the cochlear-implant business and completed in May 2024. Cochlear accepted responsibility for supporting approximately 20,000 existing Oticon Medical cochlear-implant recipients, integrating them into its long-term support infrastructure. Cochlear’s current strategy combines implant innovation with digital connectivity, services, clinical evidence, and recipient community programs. The 2025 Nucleus Nexa System introduced internal implant memory, onboard intelligence, and upgradeable implant firmware, allowing future functionality to be delivered through both implanted and external hardware. The same period brought new Baha and Kanso products and further development of remote-care and smartphone ecosystems. The company continues to describe its role as providing a lifelong hearing journey, supported by clinicians, researchers, educators, families, and recipient communities around the world.

1. 2026Nexa System launched in South Korea

   Cochlear launched the Nucleus Nexa System for Korean recipients at the 2026 World Congress of Audiology.

   Source
2. 2025Nucleus Nexa System launched

   Cochlear launched the Nucleus Nexa System with an implant featuring internal memory and upgradeable firmware, together with Nucleus 8 Nexa and Kanso 3 Nexa processors.

   Source
3. 2024Oticon Medical cochlear-implant transaction closes

   Cochlear completed the acquisition of the Oticon Medical cochlear-implant business and assumed support responsibilities for its existing recipients.

   Source
4. 2022Nucleus 8 processor and Oticon Medical agreement

   Cochlear released the Nucleus 8 processor and announced an agreement to acquire Oticon Medical’s hearing-implant business from Demant.

   Source
5. 2020Kanso 2 processor released

   Kanso 2 provided a smaller off-the-ear processor compatible with the Nucleus Smart App and related accessories.

   Source
6. 2019Osia system introduced

   The Osia active osseointegrated hearing system and Osia 2 sound processor received FDA approval, expanding Cochlear’s bone-conduction portfolio.

   Source
7. 2017Nucleus 7 processor released

   The Nucleus 7 added direct streaming from compatible Apple devices, smartphone control, and improved battery performance.

   Source
8. 2016Kanso one-piece processor released

   Cochlear launched its first one-piece off-the-ear sound processor, designed to be discreet and easier to conceal beneath hair or a hat.

   Source
9. 2015Nucleus Profile implant approved

   The Nucleus Profile implant succeeded the Nucleus 24 platform and emphasized a thin implant profile and structural strength.

   Source
10. 2014Nucleus L24 Hybrid receives FDA approval

    The Nucleus L24 Hybrid implant was approved for adults with severe-to-profound high-frequency loss and useful residual low-frequency hearing.

    Source
11. 2013Nucleus 6 processor released

    The Nucleus 6 processor introduced a smaller form factor and updated processing while retaining broad backward compatibility with earlier Nucleus implants.

    Source
12. 2011CI500 voluntary recall

    Cochlear recalled the CI500 range after reports of device shutdowns and temporarily returned to the CI24RE platform.

    Source
13. 2009CI500 implant family launched

    Cochlear introduced the CI500 family, a major implant generation that was later subject to a voluntary recall in 2011.

    Source
14. 2005Freedom implant and processor generation

    The Freedom generation brought improved sound processing and rechargeable power options to Cochlear’s product portfolio.

    Source
15. 2004Entific Medical Systems acquired

    Cochlear acquired Entific Medical Systems, expanding into bone-anchored hearing products and forming the basis of its Baha business.

    Source
16. 1998Nucleus 24 family introduced

    The Nucleus 24 family was approved, incorporating a removable magnet intended to make MRI management easier and supporting a new generation of implant and processor compatibility.

    Source
17. 1995Cochlear becomes publicly listed

    Cochlear became a separate publicly listed company during the breakup of Pacific Dunlop.

    Source
18. 1990Pediatric indication expands

    FDA authorization for the Nucleus 22 expanded to children aged two and older following clinical trials.

    Source
19. 1985Nucleus 22 receives FDA approval

    The CI22M Nucleus 22 became the first multichannel cochlear implant to receive US FDA approval.

    Source
20. 1982First commercial Nucleus cochlear-implant implantation

    The first commercial implantation of a Nucleus cochlear implant took place, marking the transition from research development to clinical commercialization.

    Source
21. 1981Cochlear is established as a Nucleus subsidiary

    Cochlear was formed to commercialize the multichannel cochlear-implant technology developed through Professor Graeme Clark’s Australian research program, with Australian government financial support.

    Source

A specialist, innovation-led medical-device brand positioned around implantable hearing restoration, clinical reliability, lifelong recipient support, connectivity with digital devices, and a broad ecosystem spanning surgery, rehabilitation, upgrades, accessories, and remote care.

• Nucleus Nexa SystemCochlear implant system2025

  Cochlear’s next-generation cochlear-implant platform, launched in 2025. It combines the Nucleus Nexa Implant with Nucleus 8 Nexa and Kanso 3 Nexa sound processors. Its distinguishing architecture includes implant internal memory, onboard diagnostics, and upgradeable firmware intended to allow future capabilities to be delivered through the implanted system as well as the external processor. The system is supported by the Nucleus Smart App, SmartNav, Custom Sound Pro fitting software, and connected-care tools.

• Nucleus cochlear implant systemsCochlear implant system1982

  The Nucleus family is Cochlear’s core cochlear-implant franchise. It includes surgically implanted electrode and receiver-stimulator assemblies, external sound processors, magnets and coils, fitting software, batteries, wireless accessories, and clinical support. The family has developed through the Nucleus 22, Nucleus 24, CI500, Profile, Profile Plus, and Nexa generations. Compatibility across generations and the availability of processor upgrades are central elements of the product proposition.

• Nucleus 8 Sound ProcessorBehind-the-ear sound processor2022

  The Nucleus 8 is a behind-the-ear processor introduced in 2022. It uses Cochlear’s adaptive hearing-processing technologies, supports wireless connectivity and direct streaming options, and works within the Nucleus implant ecosystem. The Nucleus 8 Nexa version is paired with the Nexa Implant and adds the capabilities associated with the Nexa platform. The processor is designed for use across everyday listening environments and can be managed through Cochlear’s digital tools.

• Kanso 3 and Kanso 3 Nexa Sound ProcessorsOff-the-ear sound processor2025

  Kanso 3 is Cochlear’s off-the-ear processor generation for recipients who prefer a compact, discreet form factor without a behind-the-ear unit. Kanso 3 Nexa is the version designed for the Nucleus Nexa Implant, while Kanso 3 also provides an upgrade path for some recipients using legacy Nucleus systems. The family incorporates current Nucleus processing features, wireless connectivity, smartphone support, and accessories intended for daily wear.

• Nucleus 7 Sound ProcessorBehind-the-ear sound processor2017

  Released in 2017, the Nucleus 7 was a major connectivity-oriented processor generation. It enabled direct audio streaming from compatible Apple devices, offered smartphone control through the Nucleus Smart App, supported bimodal configurations with selected ReSound hearing aids, and provided improved battery life over the Nucleus 6. It remained an important processor platform before being listed by Cochlear as discontinued in January 2026.

• Kanso 2 Sound ProcessorOff-the-ear sound processor2020

  Kanso 2 is a compact off-the-ear processor launched in 2020. It is smaller than the original Kanso and uses the same broad app and accessory ecosystem as the Nucleus 7. The design is intended for recipients who prefer a processor positioned over the implant rather than behind the ear. Its off-ear architecture does not provide the same electric-acoustic stimulation configuration as certain behind-the-ear processors.

• Osia SystemActive osseointegrated hearing system2019

  The Osia System is an active osseointegrated bone-conduction hearing solution for selected conductive, mixed, and single-sided hearing-loss indications. It uses an implanted component and an external sound processor to transmit sound through bone conduction. The platform was introduced with the OSI200 implant and Osia 2 processor in 2019 and is positioned as a discreet, connected alternative within Cochlear’s broader hearing-implant portfolio.

• Baha SystemBone-conduction hearing system2004

  The Baha portfolio includes implantable, nonsurgical, and softband-based bone-conduction solutions. Products are designed for people whose hearing loss prevents conventional air-conduction hearing aids from providing adequate benefit, including some conductive and mixed losses and single-sided deafness cases. The portfolio includes Baha implants, sound processors, Baha Start, Baha SoundBand, wireless accessories, and the Baha 7 processor introduced in 2025.

• Auditory brainstem implantsAuditory brainstem implant1990

  Cochlear auditory brainstem implants are designed for selected patients who cannot use a conventional cochlear implant because the cochlea or auditory nerve is unavailable or unsuitable. Rather than stimulating the cochlea, the implant uses an electrode array positioned near the cochlear nucleus in the brainstem. The product lineage includes the Nucleus 22 ABI, Nucleus ABI24, and later Profile ABI systems.

• Wireless accessories and connected-care toolsAccessories and software2013

  Cochlear’s accessory ecosystem includes TV streamers, wireless microphones, phone clips, waterproofing products, remote controls, rechargeable batteries, coils, retention solutions, and compatible classroom or FM receivers. Software and digital services include the Nucleus Smart App, Custom Sound Pro fitting software, SmartNav, and Remote Care. These tools extend the usefulness of the implanted system and support clinical management and everyday communication.

• 2026Cochlear Academic Scholarships

  United States

  Cochlear North America continued its annual scholarship program in 2026, recognizing students who use Nucleus, Baha, or Osia systems and promoting educational achievement, leadership, and community contribution.

  Outcome. The 2026 recipients were announced in February 2026 as part of International Cochlear Implant Day activity.

  Source
• 2025Nucleus Nexa launch campaign

  United States · Australia · Europe · Other launch markets

  The launch campaign presented the Nucleus Nexa System as a new generation of smart cochlear-implant technology. Communications emphasized implant firmware updates, internal memory, connected care, future-ready design, and smaller sound processors.

  Outcome. The system entered commercial availability in 2025, with shipments beginning in August and regional launches continuing afterward.

  Source
• 2025Address your hearing loss now

  United States

  A consumer education and lead-generation campaign encouraged adults with significant hearing loss to investigate cochlear-implant candidacy. It used recipient stories, explanatory content, and comparisons between hearing-aid amplification and implant-based hearing clarity.

  Outcome. The campaign directed prospective recipients toward information, community support, and clinical evaluation resources.

  Source
• 2010Hear now. And always.

  Global

  Cochlear’s long-running brand platform expresses a commitment to hearing support not only at implantation but throughout the recipient’s lifetime. It links product innovation, upgrades, clinical partnerships, recipient stories, community activity, and after-care under a promise of continuity.

  Outcome. The phrase became a central part of Cochlear’s global brand identity and recipient communications.

  Source
• 2010Anders Tjellström Scholarship

  North America · Other Cochlear markets

  The scholarship recognizes recipients of Cochlear Baha or Osia systems and supports further academic or vocational study. It forms part of Cochlear’s community-engagement efforts for recipients across its implant categories.

  Outcome. The program remains active alongside Cochlear’s Graeme Clark Scholarship and other recipient awards.

  Source
• 2003Graeme Clark Scholarship

  Australia · New Zealand · United Kingdom · United States · Other Cochlear markets

  Named after Professor Graeme Clark, the scholarship supports academically accomplished Cochlear Nucleus implant recipients and connects the company’s innovation heritage with education, advocacy, and recipient achievement.

  Outcome. The program continues to be promoted through annual scholarship announcements and recipient storytelling.

  Source

• 2025Launch the Nucleus Nexa SystemProduct launch

  Cochlear’s prior product generations delivered most technology improvements through the external sound processor. The company sought to create a platform that could be updated through both the implanted and external components.

  What changed. Cochlear launched the Nucleus Nexa System with an implant containing internal memory, onboard diagnostics, and upgradeable firmware, paired with Nucleus 8 Nexa and Kanso 3 Nexa processors.

  Aftermath. The launch repositioned Cochlear’s product strategy around a future-ready implant architecture, connected care, easier processor replacement, and the possibility of future firmware-enabled enhancements.

  Source
• 2022Agree to acquire Oticon Medical’s hearing-implant businessM&A

  Demant decided to exit the hearing-implant business, while Cochlear sought to strengthen its implant portfolio and support more patients in the global hearing-implant market.

  What changed. Cochlear announced an agreement to acquire Oticon Medical for an announced headline value of approximately A$170 million. Competition review later required the transaction scope to be narrowed to the cochlear-implant business.

  Aftermath. The cochlear-implant transaction closed in May 2024. Cochlear assumed support responsibilities for approximately 20,000 Oticon Medical cochlear-implant recipients, while the Ponto and Sentio bone-conduction businesses remained outside the completed transaction.

  Purchase consideration. Announced transaction value of approximately A$170 million → Zero-headline purchase price reported at completion for the acquired cochlear-implant business (2022 announcement to May 2024 completion)

  Source
• 2011Voluntarily recall CI500 implantsOther

  Some CI500 implants, particularly CI512 devices, experienced shutdowns or soft failures. The product range represented a substantial part of Cochlear’s sales and market reputation.

  What changed. Cochlear voluntarily recalled the CI500 family, stopped manufacturing the affected range while investigating the problem, and returned to the CI24RE implant as an interim platform.

  Aftermath. The recall caused a major share-price decline, created additional support and replacement obligations, and influenced later product-quality and reliability communications.

  CI500 recall provision. A$15.9 million provision reported in company accounts (2011 recall period)

  Source
• 2009Launch the CI500 implant familyProduct launch

  Cochlear sought to advance implant performance and create a new platform spanning several electrode and implant configurations.

  What changed. The company launched the CI500 range, including CI512, CI513, CI522, CI532, CI551, and an ABI variant.

  Aftermath. Reports of shutdown-related failures led to a full voluntary recall of the CI500 range in 2011 and a temporary return to the CI24RE platform.

  Source
• 2004Acquire Entific Medical SystemsM&A

  Cochlear was primarily known for cochlear implants but sought to address adjacent forms of hearing loss and diversify its implant portfolio.

  What changed. Cochlear acquired Swedish company Entific Medical Systems and its bone-anchored hearing technology.

  Aftermath. The transaction expanded Cochlear into bone-conduction hearing and established the Baha business as a major product category.

  Source
• 1995Separate from Pacific Dunlop and list publiclyStrategy

  Cochlear had operated within the Nucleus and Pacific Dunlop corporate structure, limiting its independence as the hearing-implant business expanded internationally.

  What changed. Cochlear became a separate publicly listed company during the breakup of Pacific Dunlop.

  Aftermath. The listing supported independent capital allocation, international expansion, research, manufacturing, and product development.

  Source
• 1981Commercialize multichannel cochlear-implant technologyStrategy

  Australian research led by Professor Graeme Clark had produced a promising multichannel implant, but the technology required manufacturing, regulatory, clinical, and commercial infrastructure to reach patients.

  What changed. Nucleus established Cochlear as a subsidiary with government-supported finance to commercialize the implant and build a sustainable hearing-implant business.

  Aftermath. The decision created the corporate platform that became Cochlear Limited and led to the first commercial Nucleus implantation in 1982.

  Source

• 2010US anti-kickback and False Claims Act settlementControversy

  Cochlear Americas paid US$880,000 to resolve allegations that its Partners Program provided improper remuneration, including credits, discounted products, gifts, travel, and other benefits to healthcare providers to induce purchases or use of Cochlear devices for Medicare and Medicaid patients. The settlement resolved allegations and did not constitute an admission of liability by the company.

  Source

• 2026Cochlear announces 2026 academic scholarship recipients

  Cochlear North America announced recipients of its academic scholarships for cochlear-implant and bone-conduction-system users, continuing its community and education-support programs.

  CampaignOther
  Source
• 2025Cochlear announces Nucleus Nexa System

  Cochlear announced the Nucleus Nexa System, featuring an implant with internal memory and upgradeable firmware, together with Nucleus 8 Nexa and Kanso 3 Nexa sound processors.

  Product launchProduct generation
  Source
• 2025Cochlear launches Baha 7 Sound Processor and Baha SoundBand

  The company introduced the Baha 7 processor with Bluetooth LE Audio and Auracast capabilities, alongside a redesigned Baha SoundBand for non-surgical bone-conduction use.

  Product launchProduct generation
  Source
• 2025Cochlear appoints new regional presidents and CFO

  Cochlear’s executive structure listed Sarah Thom as CFO, Stu Sayers as President of Asia Pacific and Latin America, and Anthony Bishop as President of Europe, Middle East and Africa from January 2025.

  Leadership change
  Source
• 2024Cochlear completes acquisition of Oticon Medical cochlear-implant business

  The transaction initiated in 2022 closed in May 2024 after the scope was narrowed to the cochlear-implant business. Cochlear assumed ongoing support responsibilities for existing Oticon Medical cochlear-implant recipients.

  M&A
  Source
• 2011Cochlear recalls CI500 implant range

  Cochlear voluntarily recalled the CI500 implant range after reports of devices shutting down. The event led to a temporary return to the CI24RE implant platform and a significant decline in the company’s share price.

  RecallOther
  Source
• 2011Cochlear receives recognition for innovation

  Forbes listed Cochlear among the world’s most innovative companies, following earlier recognition as Australia’s most innovative company in 2002 and 2003.

  Other
  Source
• 2004Cochlear acquires Entific Medical Systems

  The acquisition expanded Cochlear beyond cochlear implants into bone-anchored hearing technology and established the strategic basis for the Baha product business.

  M&A
  Source

1. Cochlear Limited
2. Cochlear Board of Directors
3. Cochlear Executive Team
4. Cochlear Products and Accessories
5. Cochlear launches the Nucleus Nexa System
6. Cochlear Nucleus Nexa System product page
7. Cochlear device-generation timeline
8. Cochlear completes acquisition of Demant’s cochlear-implant business
9. US Department of Justice settlement with Cochlear Americas
10. Cochlear Nucleus Reliability Report
11. Cochlear North America 2026 scholarship announcement
12. Cochlear launches Nucleus Nexa in South Korea
13. Hear now. And always.
14. Graeme Clark Scholarship
15. Address your hearing loss now
16. CI500 recall provision
17. Agree to acquire Oticon Medical’s hearing-implant business
18. Cochlear launches Baha 7 Sound Processor and Baha SoundBand